United States securities and exchange commission logo





                             January 14, 2021

       Michael Shleifer
       Chief Executive Officer
       Biotech Acquisition Company
       545 West 25th Street, 20th Floor
       New York, NY 10001

                                                        Re: Biotech Acquisition
Company
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed January 12,
2021
                                                            File No. 333-251834

       Dear Mr. Shleifer:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
November 18, 2020 letter.

       Amendment No. 1 to Registration Statement on Form S-1

       Exhibit 4.4, page 16

   1.                                                   Section 9.8 of your
warrant agreement appears to state that certain modifications or
                                                        amendments, including
any amendment to increase the Warrant Price or shorten the
                                                        Exercise Period, shall
require the vote or written consent of the registered holders of a
                                                        majority of the
then-outstanding public warrants. However, disclosure on page 50 of your
                                                        prospectus states that
the approval by the holders of at least 65% of the then-outstanding
                                                        public warrants is
required to make any change that adversely affects the interests of the
                                                        registered holders of
public warrants. The provision and your disclosure appear to be
                                                        inconsistent. Please
revise or advise.
 Michael Shleifer
Biotech Acquisition Company
January 14, 2021
Page 2


        You may contact Yong Kim, Staff Accountant, at (202) 551-3323 or Gus
Rodriguez,
Accounting Branch Chief, at (202) 551-3752 if you have questions regarding
comments on the
financial statements and related matters. Please contact Anuja A. Majmudar,
Attorney-Adviser,
at (202) 551-3844 or, in her absence, Loan Lauren Nguyen, Legal Branch Chief,
at (202) 551-
3642 with any other questions.



                                                          Sincerely,
FirstName LastNameMichael Shleifer
                                                          Division of
Corporation Finance
Comapany NameBiotech Acquisition Company
                                                          Office of Energy &
Transportation
January 14, 2021 Page 2
cc:       Lawrence A. Rosenbloom, Esq.
FirstName LastName